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Pelvic floor rehabilitation to improve
functional outcome and quality of life after
surgery for rectal cancer: study protocol for
a randomized controlled trial (FORCE trial)
A.J. Kalkdijk-Dijkstra1, J.A.G. van der Heijden2, H.L. van Westreenen3, P.M.A. Broens1, M. Trzpis1, J.P.E.N. Pierie1,4,5,
B.R. Klarenbeek2* and FORCE Trial Group
Abstract
Background: After low anterior resection (LAR), up to 90% of patients develop anorectal dysfunction. Especially
fecal incontinence has a major impact on the physical, psychological, social, and emotional functioning of the
patient but also on the Dutch National Healthcare budget with more than €2000 spent per patient per year. No
standardized treatment is available to help these patients. Common treatment nowadays is focused on symptom
relief, consisting of lifestyle advices and pharmacotherapy with bulking agents or antidiarrheal medication. Another
possibility is pelvic floor rehabilitation (PFR), which is one of the most important treatments for fecal incontinence
in general, with success rates of 50–80%. No strong evidence is available for the use of PFR after LAR. This study
aims to prove a beneficial effect of PFR on fecal incontinence, quality of life, and costs in rectal cancer patients after
sphincter-saving surgery compared to standard treatment.
Methods: The FORCE trial is a multicenter, two-armed, randomized clinical trial. All patients that underwent LAR are
recruited from the participating hospitals and randomized for either standard treatment or a standardized PFR
program. A total of 128 patients should be randomized. Optimal blinding is not possible. Stratification will be done
in variable blocks (gender and additional radiotherapy). The primary endpoint is the Wexner incontinence score;
secondary endpoints are health-related and fecal-incontinence-related QoL and cost-effectiveness. Baseline
measurements take place before randomization. The primary endpoint is measured 3 months after the start of the
intervention, with a 1-year follow-up for sustainability research purposes.
Discussion: The results of this study may substantially improve postoperative care for patients with fecal
incontinence or anorectal dysfunction after LAR. This section provides insight in the decisions that were made in
the organization of this trial.
Trial registration: Netherlands Trial Registration, NTR5469, registered on 03-09-2015.
Protocol FORCE trial V18, 19-09-2019.
Sponsor Radboud University Medical Center, Nijmegen.
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Background
The treatment of rectal cancer has improved greatly over
recent years in terms of oncological outcomes. Combina-
tions of surgery, radiotherapy and/or chemotherapy are
responsible for improved survival data. Nowadays most of
these patients can be treated with a sphincter-saving tech-
nique, such as the low anterior resection (LAR). Unfortu-
nately, the majority of these patients develop anorectal
dysfunction [1], which can consist of urgency, increased
frequency of defecation, fecal incontinence, soiling, no
control on flatus or incomplete evacuation. Up to 76–90%
of these patients report a combination of these com-
plaints, which are described as low anterior resection syn-
drome (LARS) [2, 3]. Fecal incontinence especially has a
major [1, 4, 5] impact on the physical, psychological, so-
cial, and emotional functioning of the patient [3, 6].
Alongside the impact on personal life, fecal incontin-
ence has a substantial impact on the National Healthcare
budget with more than € 2000 spent per patient per year
in the Netherlands [7]. Production losses in paid and un-
paid work accounted for more than half of the total
costs, and costs of healthcare visits accounted for almost
a fifth of the total costs. One-tenth of the total cost is
associated with protective material (only partially re-
imbursable), while incontinence medication was only
responsible for 5% of the total costs [7]. Currently, the
exact prevalence of LARS in the Netherlands is un-
known, but an increase in the numbers of patients
suffering LARS in the Netherlands is expected due to
the start of colorectal cancer screening in January 2014
among men and women between 55 and 75 years.
Despite the large impact of LARS, no gold standard
exists to treat these patients in a way that focuses on the
cause of the problem. The current standard treatment is
focused on symptom relief, consisting of pharmacother-
apy with bulking agents and/or anti-diarrheal medica-
tion. However, no sustained clinical improvements of
these therapies in LARS patients have been reported.
Pelvic floor rehabilitation (PFR) is one of the most im-
portant treatments for fecal incontinence in general,
with success rates of 50–80% [8–10]. Based on previous
studies, we hypothesize that PFR might reduce the num-
ber and severity of fecal incontinence after rectal resec-
tions by 25% (measured by the Wexner score) [11–15].
The FORCE trial randomizes rectal cancer patients
after sphincter-saving rectal resection for either a stan-
dardized pelvic floor rehabilitation program or standard
treatment to investigate which arm results in a greater
decrease of complaints and costs of fecal incontinence.
Methods/Design
Study design and research questions
The FORCE trial is a multicenter, two-armed, random-
ized controlled trial. The severity of fecal incontinence
(FI) in patients after LAR will be measured by the Wex-
ner score. Secondary study objectives are to determine
the effect of PFR compared to standard treatment on the
quality of life (by measuring the fecal incontinence qual-
ity of life and using the EORTC Colorectal Quality of
Life Questionnaire QLQ-CR29), to analyze the cost
effectiveness of full implementation of PFR compared to
present daily practice (standard treatment) in treating
and preventing functional bowel complaints in patients
after LAR. In addition, this study aims to explore the
effect of demographic, surgical and oncologic parameters
on the development of FI after LAR relative to PFR and
standard treatment.
Study population
The study population consists of rectal cancer patients
living in the Netherlands who undergo sphincter saving
surgery (low anterior resection, LAR) in one of the par-
ticipating hospitals (n = 17): Radboud University Medical
Center Nijmegen, University Medical Center Groningen
(UMCG), Medical Center Leeuwarden (MCL), Isala
Clinics Zwolle, Antonius Hospital Sneek, Nij Smellinghe
Drachten, Ommelander Hospital Groningen (OZG),
Canisius-Wilhelmina Hospital (CWZ) Nijmegen,
Deventer Hospital, Slingeland Hospital Doetinchem,
Máxima MC (MMC) Veldhoven/Eindhoven, Treant
Zorggroep Emmen, Bernhoven Uden, Tjongerschans
Heerenveen, Elizabeth TweeSteden Ziekenhuis (ETZ)
Tilburg, Maasziekenhuis Pantein Boxmeer, and Streek-
ziekenhuis Koningin Beatrix (SKB) Winterswijk. In each
center, a principal investigator is assigned for inclusion
and informed consent (Additional file 1). In case of a
temporary stoma, patients can participate until 6 weeks
after closure. Without a temporary stoma, patients can
participate 3 months after closure. Inclusion criteria are
(1) adults (≥18 years), (2) LAR for rectal carcinoma, and
(3) being intellectually and/or linguistically capable of
understanding the questionnaires. Patients with a history
of proctitis, colitis ulcerosa, or Crohn’s disease; a life
expectancy of less than 1 year; and mental or physical in-
abilities to undergo PFR are excluded. Participants with
locally advanced (T4) tumors indicated for extensive
resection (beyond TME) and patients who received
invasive physiotherapy during the previous 6 months are
excluded as well.
Flow of the FORCE trial
After surgery, eligible patients will be randomized for
either a standardized pelvic floor rehabilitation (PFR)
program or standard treatment, which is defined as
current daily practice. Blinding for PFR is not possible.
Randomization and data collection will be performed by
the coordinating investigator. In concordance with the
study flowchart (Fig. 1), these steps will be followed:
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1. After giving informed consent, eligible patients
will be included in the FORCE trial. In the
beginning of the inclusion period, this inclusion
was supposed to occur preoperatively with a
baseline measurement before surgery as well
(measurement 1, M1). Since this preoperative
inclusion led to reduced numbers of inclusion
due to an overload of information, postoperative
inclusion was allowed as well.
2. Questionnaires will be administered 3 months after
LAR (measurement 2, M2) to patients without a
temporary stoma. Based on the current reports,
approximately 70% of patients undergoing LAR also
receive a temporary stoma [16]. In these cases, the
questionnaires will be administered 6 weeks after
stoma closure (measurement 2, M2).
3. Randomization will take place after completing the
M2 questionnaires. Patients will then undergo
Fig. 1 Flowchart of the FORCE trial. Abbreviations: M1–4, measurement 1 till 4. LAR, low anterior resection
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either standard treatment or a standardized PFR
program that includes the standard treatment for 3
months (12 sessions, once a week).
4. After finishing the PFR program or 12 weeks of
participation in the control group, questionnaires
will be send again (measurement 3, M3, primary
endpoint).
5. Long-term follow-up will be completed at 1 year
after bowel continuity (measurement 4, M4).
Patients who decline the request for participation will
be asked to fill out the DeFeC questionnaire (with Wex-
ner score included) and LARS score only one time.
These patients will sign a separate informed consent
form for this step (Additional file 2). Study participation
for these patients will stop directly after finishing these
questionnaires. By means of this questionnaire, a valid
statement can be made about the potential selection bias
for participation that is based on the amount of complaints.
Patients from the control group who would like to
undergo PFR will be given the opportunity to undergo
this treatment after finishing measurement 3 (M3).
These patients will undergo an identical PFR program as
the patients that are initially randomized to this inter-
vention and will be asked to fill in another question-
naire (similar to M2/M3) after their treatment. This
might provide useful information about whether the tim-
ing of PFR is of influence on the results.
This study protocol is in accordance with the 2013
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Statement [17]. The checklist
can be found in Additional file 3. The schedule of enroll-
ment, interventions, and assessments is shown in
Table 1.
Recruitment and informed consent
The Committee on Research Involving Human Subjects
Arnhem-Nijmegen approved the FORCE trial. All pa-
tients with proven colorectal cancer will be treated ac-
cording to standard surgical protocols. Patients who
meet the inclusion/exclusion criteria will be selected and
asked for participation for this study by their own sur-
geon. The surgeon will inform the patients by handing
out the patient information and will ask for permission
to inform the coordinating investigator about his/her
possible participation. This step will be noted in the
electronic health records. After a reasonable time (2
weeks), the coordinating researcher will call the patient
to answer potential questions. The patients will have 2
weeks to consider before renewed contact is made.
When patients decide to participate, they will sign the
Informed Consent and send it to the coordinating inves-
tigator at Radboud University Medical Center (Radbou-
dumc). The coordinating investigator will be responsible
for storing the signed Informed Consent in the Trial
Master File at Radboudumc and in the investigator site
files at the participating centers. On the consent form,
participants will be asked if they agree to the use of their
data. Participants will also be asked for permission for
the research team to share data with the regulatory
authorities, where relevant.
Randomization, stratification, and blinding
Randomization and stratification
Randomization will be performed 3months after the
LAR in patients without stoma construction, and in case
of a temporary stoma, 6 weeks after stoma closure. The
coordinating investigator will conduct the randomization
procedure, using Castor EDC (www.castoredc.com).
Table 1 The schedule of enrollment, interventions, and assessments (according to the SPIRIT statement 2013)
TIME POINT STUDY PERIOD
Enrollment Allocationa Post-allocation Close-out
October 2017 – December 2019 0 t1
b t2
b t3




Randomization and allocation X
INTERVENTIONS:
Pelvic Floor Rehabilitation X
Control group X
ASSESSMENTS:
Questionnaires to assess study outcomes X X X
Statistical analysis X
aAllocation of the intervention/control group takes place 3months after index surgery without temporary stoma construction or 6 weeks after stoma reversal if
initial surgery included stoma construction. Measurement t1 will always take place before randomization/allocation
bt1 measurement before randomization, t2 primary endpoint (12 weeks after control/intervention period), t3 one year follow-up
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Stratification will be done in variable blocks. It will be
stratified for gender and radiation because of frequent
sphincter function impairment due to birth trauma in
women and the association between radiation and
sphincter and bowel dysfunction. The coordinating
investigator will be responsible for communication with
the pelvic floor specialized physiotherapists and will in-
form them about referral and the allocated intervention.
Blinding
The physiotherapists will be informed about the pre-
and postoperative medical history of the patient. Sur-
geons and physiotherapists are blinded in terms of
outcomes of questionnaires taken before the start of PFR
(measurement M2, Fig. 1). Complete blinding of the
allocated intervention for patients and the participating
physiotherapists is impossible. Unblinding will not
occur, since the design is open label. The coordinating
investigator, who will also be involved in data analysis, is
not blinded for the allocation since he will inform the
physiotherapists about referral and the allocated inter-
vention. Additional data analysists will be blinded for
allocation.
Data analysis and statistics
Primary outcome
The primary outcome is based on the Wexner score.
The dependent variable is the severity of FI measured by
this score. The independent variable is the intervention
or the standard treatment. The difference between the
intervention and control group will be analyzed by an
analysis of covariance (ANCOVA), with the baseline
measurement as covariate. This test is preferred over the
T-test since this analysis reduces the within-group error
variance. Therefore, the precision of the treatment esti-
mate is increased, and the length of the confidence inter-
val is reduced [18]. The M3 measurement will be valid
as the primary outcome. The M4 measurement, which is
used to assess sustainability of results, will be influenced
by the patients of the control group who will choose to
undergo PFR after finishing their primary endpoint mea-
surements (after 3 months of standard treatment, i.e., in
case of severe FI). For statistical analysis, the effect
between the intervention group and control group will
be evaluated with and without this group to measure the
influence of this group on the M4 measurement. The
same analysis of covariance (ANCOVA) will be used.
Secondary endpoints
– The economic effects of full implementation of PFR
compared to standard treatment in treating and
preventing FI in patients after LAR will be
determined by a cost effectiveness analysis. This will
be evaluated by regression analysis (see subheading
“cost effectiveness analysis” below for detailed
methods).
– The effect of the demographic, surgical, and
oncologic parameters on the development of FI after
LAR relative to PFR and standard treatment will be
explored.
– The effect of PFR compared to standard treatment
on anorectal outcomes in patients after LAR by the
DeFec, LARS score, and defecation log will be
determined.
– The effect of PFR compared to standard treatment
on QoL by means of the Fecal Incontinence Quality
of Life (FIQL), EORTC Colorectal Quality of Life
Questionnaire QLQ-CR29, and EQ5D will be
determined. The latter evaluation will be used for
economic evaluations in particular.
The dependent variable is the degree of QoL/anorectal
outcome. The independent variable is the intervention
or the standard treatment. The difference between the
effect in the intervention group and the control group
will be analyzed by analysis of covariance (ANCOVA) as
well. No additional analyses, such as subgroup analysis,
are written out in advance.
Intention to treat and per protocol analysis
Primary study outcome will be based on intention to
treat analysis. In addition, per protocol analysis will be
performed. This analysis will be done to avoid the effects
of crossover, protocol violation, and dropout.
Handling and storage of data and documents
The anonymized data will be stored in Castor EDC.
Only the coordinating and principal investigators will
have access to the key of the code that matches partici-
pants to study data. Most patients will fill in their ques-
tionnaires themselves online. Only those without email
will fill in the paper version of the questionnaires.
No specific plans, besides an active attitude towards
the participating centrums, are made to promote partici-
pant retention and complete follow-up. If patients fail to
start/continue their allocated intervention (Pelvic Floor
Rehabilitation, since failure of control group is not
possible), data will be collected according to the study
protocol for use in per protocol analysis.
Sample size calculation
Recent studies reported an improvement of FI after LAR
by PFR of five points on the Wexner-score (SD = 8) [11,
12, 15]. This improvement is considered to be of great
clinical significance.
In the original design of this trial, an independent T-
test was suggested for the primary outcome measure.
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Progressive insights made it possible to make a change
to the ANCOVA analysis, since this test reduces the
within-group error variance. Therefore, the precision of
the treatment estimate has been increased, and the
length of the confidence interval has been reduced [18].
Therefore, for this trial with an ANCOVA as primary
statistical test, the following sample size calculation was
made:
1) The T-test sample size was based on 80% power to
detect a difference of five points in the Wexner
score, SD = 8, two-grouped t-test, with a 0.05 two-
side significance level: 63 patients per arm.
2) The sample size calculation for analysis of
covariance (ANCOVA) in randomized clinical trials
described by Borm et al. [18] was used, with an
estimated correlation factor (R) of 0.5. The required
sample size is 32 patients per arm.
3) Assuming a withdrawal/replacement rate of 50%
[11, 12, 15], a total of 128 patients should be
randomized.
Data monitoring, harms, and auditing
The Committee on Research Involving Human Subjects,
Arnhem-Nijmegen approved this study and declared it
as a “negligible risk” study. Therefore, no Data Safety
Monitoring Board is needed, and no interim analysis or
formal stopping rules for the trial are needed to be con-
ducted or formulated. No anticipated harms exist, nor
will compensation be provided for trial participation. No
need for post-trial care is expected. Monitoring will
occur with a frequency of one visit per year per center,
in which the following items will be checked: informed
consents, availability of data in Trial Master File and In-
vestigator Site Files, inclusion and exclusion criteria,
SAEs, and source data verification. Trial auditing will be
twice a year since that is the frequency of meeting with
the Trial Steering Group of principal investigators. Any
solicited and spontaneously reported adverse events and
other unintended effects of the trial will be reported to
the Committee on Research Involving Human Subjects,
Arnhem-Nijmegen, who will review the situation and
give appropriate advice regarding expectedness, serious-
ness, severity, and causality.
Patient information and questionnaires
Medical history/patients characteristics
The patient information will include the medical history,
gender, age, tumor height (MRI and scoping), height and
type of the anastomosis, type of surgery (laparoscopic,
open or robotic), construction of a temporary stoma,
peri- and postoperative complications, time of surgery,
blood loss, time of hospitalization, and clinical and
pathological TNM staging.
Groningen defecation and fecal continence (DeFeC)
This questionnaire incorporated various Rome IV cri-
teria and scoring tools for severity of constipation and
fecal incontinence. Overall reproducibility of the Gro-
ningen DeFeC questionnaire is acceptable and its validity
is good [19]. This makes it a feasible screening tool for
defecation disorders. The primary outcome, the Wexner
score, will be derived from this questionnaire. The distri-
bution of subtypes and symptoms of fecal incontinence
in the general Dutch population has already been inves-
tigated with the use of this questionnaire [20].
Wexner incontinence score
The Wexner score allows the severity of fecal incontin-
ence to be assessed using five questions (Table 2). The
minimal score patients can obtain is 0 (continent), and
the maximum score is 20 (highest severity of incontin-
ence). This score describes the type and frequency of the
incontinence and impact on daily life. No data exist
about the internal consistency and the criteria/content
validity of this score. The intraclass correlation coeffi-
cient (ICC) of the Wexner score is good to excellent
(ICC 0.75). The construct validity is R(Pearson) = 0.78
(correlation with Vaizey score) [21]. The Wexner score
has an important association with the Fecal Incontinence
Quality of Life score (r = − 0.45), but a weak correlation
with changes in the EQ-5D has been described [22].
LARS score
The LARS score is a validated scoring system for bowel
dysfunction after low anterior resection for colorectal can-
cer. The Dutch version was recently validated [23]. This
score covers the five most bothersome issues in terms of
prevalence and impact of QoL, namely incontinence for
flatus and liquid stool, frequency, clustering, and urgency.
Scores range from 0 to 42, with subdivisions in three cat-
egories: no (0–20), minor (21–29), and major LARS (30–
42). A statistically significant association exists between a
higher LARS score and an impaired QoL. The test-retest
reliability of the LARS score is good, with an interclass
correlation coefficient of 0.79 [23].




Never Rarely Sometimes Usually Always
Solid 0 1 2 3 4
Liquid 0 1 2 3 4
Gas 0 1 2 3 4
Wears pad 0 1 2 3 4
Lifestyle alteration 0 1 2 3 4
Never, 0; rarely, < 1/month; sometimes, < 1/week, ≥1/month; usually, < 1/day,
≥1/week; always, ≥1/day
0, perfect; 20, complete incontinence
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Fecal incontinence quality of life score (FIQL score)
The FIQL score is a condition-specific questionnaire on
quality of life and consists of four multi-item subscales:
lifestyle (10 items), coping/behavior (nine items), depres-
sion/self-perception (seven items), and embarrassment
(three items), for a total of 29 items [24]. Each item has
four answer opportunities, with a score of 1 to 4, where
1 indicates a low quality of life and 4 a high quality
of life.
The internal consistency (Cronbach’s α) is good (sub-
scale 1, 0.96; subscale 2, 0.96; subscale 3, 0.88; and sub-
scale 4, 0.80). The total FIQL has an adequate internal
and external responsiveness (standardized response
mean = 0.5, r = − 0.48, and area under the curve = 0.765).
The intraclass correlation coefficient is good to excel-
lent: 0.80 (embarrassment) to 0.93 (lifestyle) [25].
EORTC colorectal quality of life questionnaire QLQ-CR29
Quality of life will be measured by the EORTC Colorec-
tal Quality of Life Questionnaire QLQ-CR29. The ICC
of the QLQ-CR29 is good to excellent (Intraclass Correl-
ation Coefficient: 0.78) [26, 27]. The Internal consistency
of this questionnaire reaches the criterion of 0.70 [26].
Defecation and urinary log
This log provides insight into the defecation pattern,
type of consistency (Bristol Stool Form Scale) [28], feel-
ing of urge to defecate, episodes of fecal incontinence,
and the use of diapers. Also, the use of medication will
be noted. The patient will keep up this log 5 days per
week after LAR or temporary stoma from the moment
of randomization until the end of the intervention (3
months). This log will be used to allow discussion about
the number of treatment sessions that will be needed to
obtain an effect of PFR. Fecal incontinence occurs often
in combination with incontinence for urine. In case of
urine incontinence, the patient has to keep up the sever-
ity and episodes of this urinary incontinence. The incon-
tinence will namely influence the costs (i.e., use of diapers).
Cost effectiveness analysis (CEA)
The economic evaluation investigates, alongside the clin-
ical trial, the value for money of full implementation of
the standardized pelvic floor rehabilitation program
compared to the usual care. This will be done from a so-
cietal perspective. The timeframe of empirical evaluation
is 6 months. The effect at 6 months is supposed to be
sustainable for 5 years, which will be explored by
decision-analytic modelling. The design of the economic
evaluation follows the principles of a cost-utility analysis
and adheres to the new Dutch guideline for performing
economic evaluations in health care (ZINL, 2015). Fecal
incontinence-related problems are anticipated to decrease
after PFR, which would result in a reduction of health care
consumption, increased work resumption/participation,
and an increase in health-related quality of life in this tar-
get population. Cost-effectiveness will be expressed in
terms of gains in the cost per Quality Adjusted Life Year
(QALY). Uncertainty will be dealt with by one-way sensi-
tivity analysis (deterministic) and by parametric statistics,
ultimately presenting cost-effectiveness acceptability
curves. The modelling part will be probabilistic.
Cost analysis
The cost analysis exists of two main parts. First, at the
patient level, the volume of care will be measured pro-
spectively over the time path of the study using patient-
level diaries (on fecal incontinence-related health care
consumption), completed, if necessary, by data from the
patient training facility’s administration system. The
diary will be developed in a way that it structures and
makes uniform the health care consumption of a fecal
incontinent patient for this particular target population.
Second, per item of health care consumption, the stand-
ard cost will be determined using the guideline for per-
forming economic evaluations (ZINL, 2015), which will
be completed with the total costs of items via activity-
based costing. Productivity losses for patients will be
assessed using a patient-based diary complemented with
an interview on a 3-month recall basis between the
researcher and the patient (at baseline and at the 3- and
6-month follow-ups). The friction cost-method will be
applied following the Dutch guidelines (ZINL, 2015). In
addition, travel time to the training site and related costs
will be considered (also on the basis of the diary). Differ-
ences in costs between both groups will be evaluated
using regression-based techniques.
Patient outcome analysis
The effect analysis adheres to the design of the random-
ized controlled trial and measures at baseline and at
fixed points along time path/follow-up of the clinical
trial (see design clinical trial). For measurements on the
quality of the health status of the patients, a validated
so-called health-related quality of life (HR-QoL) instru-
ment—the EuroQol-5D (EQ-5D) [29]—will be used.
This HR-QoL instrument will be completed by the
patients and is available in a validated Dutch translation.
The EQ-5D-5 L which is used in this study is a generic
HR-QoL instrument comprising five domains: mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression [30, 31]. The EQ-5D-5 L index is obtained by
applying predetermined weights to the five domains.
This index gives a societal-based global quantification of
the patient’s health status on a scale ranging from 0
(death) to 1 (perfect health). Patients will also be asked
to rate their overall HR-QoL on a visual analog scale
(EQ- 5D VAS) consisting of a vertical line ranging from
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0 (worst imaginable health status) to 100 (best imagin-
able). For the EQ-5D-3 L, the version used before the
introduction of the EQ-5D-5 L, a weak correlation was
known to exist with changes on the Wexner score [22].
The same can be expected from the EQ-5D-5 L.
Budget impact analysis (BIA)
BIA will be conducted to assess how healthcare bud-
gets will be influenced when offering the standardized
pelvic floor rehabilitation program. This program is
anticipated to allow savings of €191 in direct medical
cost and €280 in productivity gains for the average
patient on a yearly basis. The patient-based budget
impact will be extrapolated to the population level.
Although the BIA relies heavily on the findings from
the economic evaluation described above, it will be
conducted from various perspectives, such as from
the broader perspective of the public purse down to
the narrow healthcare perspective. To that end, use
will be made of a health economic (decision ana-
lytical) model in which uncertainty will be taken into
account. Deterministic uncertainty concerning BIA
input, such as perspective, pricing parameters, time
horizon, uptake, etc., will be dealt with by generating
the budget impact as a series of sensitivity analyses
covering a relevant range of costs. In general, for the
BIA we adhere to the new guideline for performing
economic evaluations in health care (ZINL, 2015).
Investigational treatment
The control group
Patients in the control group will get the standard
treatment that currently is used in daily practice. This
standard treatment for postoperative FI consists of
the prescription of bulking agents (i.e., Metamucil,
psyllium fibers, Volcolon, or Normacol). Bulking
agents can be beneficial to the consistency of the
stool and therefore diminish soiling problems. These
bulking agents may be used once or twice per day de-
pending on the severity of FI. Standard oncologic
follow-up after LAR at the surgical outpatient clinic
will be provided. In case of severe FI and/or failing of
standard treatment, cross over to the intervention
group will be allowed. After finishing their allocated
control group period, these patients with severe com-
plaints might wish to undergo PFR. This will be
allowed, and these patients will receive PFR according
to the study protocol. After 12 sessions, patients will
be asked to fill in another questionnaire, which will
allow them to evaluate whether the length of the
post-operative period after which PFR has been
applied, influenced the patient’s outcomes.
The intervention group
Treatment of patients in the intervention group will
consist of four modalities of pelvic floor rehabilitation in
addition to the standard treatment:
1) pelvic floor muscle training to a) increase the max-
imum strength of muscle contraction, b) extend the time
of muscle contraction, and c) improve the coordination
of contraction of the pelvic floor muscles; 2) biofeed-
back, which is a behavioristic therapy that allows the
patient to become conscious of the contraction and
relaxation of the pelvic floor muscles and uses an anal
electromyography probe; 3) electrostimulation, which
can improve the effectiveness of the contraction strength
of the pelvic floor muscles and uses the same anal elec-
tromyography probe as used for biofeedback; and 4)
training with a rectal balloon to simulate the urgency to
defecate, which is a method that enables the patients to
train to retain stool, enabling the patient to retain a
larger stool in the rectum.
The intervention will be performed by specialized pel-
vic floor physiotherapists, registered in the Dutch
KNGF-NVFB register. These physiotherapists will be
chosen based on the location of their practices. For the
comfort of patients included in this study, the close loca-
tion of the practices to the participating hospitals is im-
portant. Therefore both hospital-based and private
practices were allowed to participate. The physiothera-
pists will be obliged to attend a course during which the
treatment protocol and the case report form will be ex-
plained. The coordinating investigator will guide this
course and will train the physiotherapists. During this
training session, the correct way of digital rectal examin-
ation to assess the function of the pelvic floor, the use of
biofeedback, electrostimulation, and the rectal balloon
will be explained and illustrated using videos. An inter-
nationally accepted protocol, The Pelvic Floor Assess-
ment Protocol, will be used for the digital rectal
examination performed by the physiotherapist (Inter-
national Continence Society 2006, Messelink et al.). The
physiotherapist will also be instructed on how to use the
case report form and report any adverse events during
the 12 sessions of PFR. Since a patient’s adherence to
PFR is a common problem, an instruction on how to en-
large this adherence to therapy will be provided [21, 22].
The complete treatment trajectory for both the control
and the intervention group will be recorded in a stan-
dardized protocol, which has already been developed by
clinical experts in the field [8].
Pelvic floor muscle training
Patients will start with the intervention trajectory 3
months after LAR or 6 weeks after stoma closure. Dur-
ing the next 3 months, they will undergo 12 treatment
sessions, once per week. The first session will take 45
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min, and the following sessions 30–35min. During every
treatment, the physiotherapist will complete a case re-
port form. This case report form contains all in-
formation concerning pelvic floor muscle training,
biofeedback, electrostimulation, peri-anal examination,
and digital rectal examination. Digital rectal examination
of pelvic floor functionality will be used to assess the
ability to consciously contract the pelvic floor muscles
and to quantify the strength of the contraction [8, 32].
The use of medication according the standard treatment
will be reported also in the case report form. All patients
randomized to the intervention group will be instructed
by their physiotherapist on how to exercise the pelvic
floor. The patients will be thought to selectively generate
voluntary contractions of the puborectal muscle and the
external anal sphincter and also how to relax these mus-
cles and to avoid co-contractions of other muscles. The
pelvic floor has to satisfy requirements of maximal
strength, progression of the duration of the strength,
and progression in timing and coordination of the con-
traction [8, 32]. Additionally, folders will be provided,
with illustrations and short descriptions of exercises,
which have to be performed at home three times per
day, preferably at fixed time points [8, 32]. The success
of PFR depends greatly on the motivation, willingness,
and self-discipline of patients to exercise at home [8, 32].
Biofeedback Biofeedback is a cognitive behavioral
therapeutic intervention, which is used during PFR exer-
cises to help patients in monitoring their pelvic floor
function. Biofeedback provides insight in the activity of
the pelvic floor and gives the patient direct feedback
during exercises [32]. Biofeedback will, if available at the
local PFR clinic, be achieved by an anal electromyog-
raphy (EMG) probe, with 24 sensory points, located at
six different heights and four different directions along
the probe. The MAPLe system is validated for its pur-
pose and the selected physiotherapists are already expe-
rienced users (MAPLe, Novuqare, the Netherlands) [24].
If this MAPLe system is not available in the participating
PFR clinic, use of the Anuprobe anal probe (Pelvitec, the
Netherlands) is acceptable to perform the described
intervention. Biofeedback will be conducted during all
PFR sessions.
Electrostimulation Electrostimulation will be used to
gain strength and effectiveness of contractions of the
pelvic floor. Especially when contractions of the pelvic
floor muscles are not observable or palpable, electrosti-
mulation is able to train the pelvic floor muscles and will
contribute to better strength of contraction [32]. Electro-
stimulation will be conducted during all PFR sessions in
combination with biofeedback using the same anal
probe.
Rectal balloon training Rectal balloon training is used
to simulate the need for defecation. During training, a
rectal balloon (Ashley Rectal Balloon, Pelvitec) will be
inserted into the neorectum (i.e., remaining part of rec-
tum and distal colon). Subsequently, the balloon will
slowly be inflated using a syringe, which is connected to
the balloon. Patients will be asked to pay attention to
their rectal filling sensations and once they feel a strong
desire for defecation, an adequate contraction of the
sphincter and puborectal muscle needs to be produced
to retain the balloon. The awareness that also their neor-
ectum can adapt fecal content and that therefore, after a
short period of active sphincter/pelvic contraction, the
urge for defecation will diminish will strengthen their
confidence in fecal continence [32]. Rectal balloon train-
ing helps to control fear of FI and allows patients to tol-
erate larger volumes of stool in the neorectum. Rectal
balloon training will not be started until the patients’
maximum pelvic floor functions is recovered. During the
last three PFR sessions, this training will be part of the
sessions anyway. Rectal balloon training will be com-
bined with biofeedback.
Use of cointerventions
In a selected case of severe FI, colon irrigation or per-
manent colostomy might be valuable alternatives when
the standard treatment does not decrease either the se-
verity of FI or diarrhea. Such procedures will be consid-
ered cointerventions. Diarrhea is frequently seen after
LAR and might contribute to the severity of FI; there-
fore, diarrhea inhibitors (usually loperamide derivates)
are often prescribed. When this medication is already
being used on a regular basis at the start of the interven-
tion, patients will be instructed to continue this during
the study. Cointerventions or any changes in medication
will be reported in the case report form by the pelvic
floor physiotherapist or the surgeon. This information
will be taken into consideration during statistical
analyses.
Discussion
To our knowledge, the FORCE trial is the first to study
the effects of a structured pelvic floor rehabilitation
(PFR) program after sphincter-saving rectal cancer sur-
gery in a prospective randomized controlled trial with a
well-defined rehabilitation program that uses all four im-
portant parts of pelvic floor training (pelvic floor muscle
training, biofeedback, electrostimulation, and rectal
balloon training) and includes an evaluation of quality of
life and cost-effectiveness.
Previous studies that evaluated PFR after low anterior
resection differed in terms of patient selection criteria
and study design but differed most of all in the PFR pro-
tocols and fecal incontinence scoring systems [11–15]
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used. Visser et al. (2014) noted the importance of con-
sistent quality of life assessment in future trials with PFR
since only one study had assessed this outcome before
[33]. This study protocol meets this need and will add a
cost-effectiveness analysis for full implementation of the
PFR.
The authors choose to publish this study protocol to
prevent wasteful duplication of research effort and
expenses but most of all to provide an insight into the
decisions that were made during designing the FORCE
trial. Several points will be discussed below.
Choices of questionnaires
The outcomes of this study will be assessed by standard-
ized questionnaires. To date no consensus exists on how
to evaluate the severity of fecal incontinence and its con-
sequences for the Quality of Life [21, 22, 34, 35]. A com-
bination of the Wexner score and FIQL score is
considered to give the most objective outcomes [21],
which is why these were incorporated into the study de-
sign. The DeFeC is used since this questionnaire incor-
porates various Rome IV criteria and scoring tools for
constipation and fecal incontinence but also has refer-
ence population data available, which is important for
the interpretation of results [20]. For a better insight into
the quality of life after LAR, the EORTC QLQ-CR29 was
chosen. This list was preferred over several other ques-
tionnaires (i.e., the RAND36 or WHOQoL) since this
one is a colorectal-specific module while the others asses
the QoL from a general point of view. The presence of
comorbidity, unrelated to defecation problems, in this
aging group of patients might otherwise interfere with
the reported quality of life.
The choices for the other questionnaires do not require
additional explanation in our opinion.
Inclusion of patients regardless of the degree of their
complaints
Where several previous studies selected patients with a
specific amount of complaints/incontinence, we choose
to include all patients without a predefined selection on
the degree of postoperative complaints. This decision
was based on the high percentage of patients that experi-
ence different types of functional bowel complaints after
LAR and the hypothesis that all patients receiving the
operation possibly could benefit from PFR. In addition,
no uniformity exists in the cut-off value for our chosen
primary endpoint, namely the Wexner incontinence
score. The additional advantage of including unselected
patients is that it allows a valid and more extensive
statement to be made about a broad spectrum of
patient’s characteristics, including their continence status,
which are important in predicting a specific outcome
after PFR.
Postoperative inclusion
The FORCE trial protocol was initially based on pre-
operative inclusion and included a preoperative meas-
urement. Unfortunately, patients experienced an
overload of preoperative information, and they stated
that they wished to focus on their planned surgery.
Therefore, we encountered serious difficulties in enrol-
ling patients in the study, which is why we chose postop-
erative inclusion only. We are aware that this decision
might introduce a selection bias, since patients already
know the severity of their complaints. To report which
specific type of patients refuse to participate, we started
to ask patients who had denied full study participation
to only fill in a single questionnaire regarding functional
bowel complaints. We are also aware of the difficulties
in reporting valid statements on the patient’s continence
level before surgery. Determining the impact of surgery
and/or radiotherapy in consideration of the preoperative
continence level of the patient would be interesting, but
this turned out to be infeasible. Since patients with ser-
ious postoperative complications (i.e., anastomotic leak-
age) are in a poor condition after surgery, this might
induce selection bias as well. Therefore, this study likely
cannot provide hard conclusions on FI and PFR after
such serious problems.
Extensive anorectal manometric and function testing
Having patients fully examined with regard to manom-
etry and anorectal functioning and objectively measuring
what the effects of PFR are after rectal surgery [36]
would have been interesting. Especially since rectal (can-
cer) surgery with the construction of a low anastomosis
might interfere with the puborectal continence reflex
[37, 38] and could induce clinical symptoms of fecal in-
continence. However, such an examination turned out
to be logistically infeasible for all patients due to the
geographical spread of hospitals throughout the country
and limited accessibility of anorectal function centers. In
addition, the anorectal function devices that are cur-
rently used show a lot of variation regarding quality of
measurements, which would make it difficult to make
valid comparisons.
As with many randomized controlled trials, the
FORCE trial is designed to make a difference in clinical
daily practice. We believe that the results of this study
can substantially improve care for patients with bowel
dysfunction after LAR for rectal cancer. Subsequently,
positive study results may be used in future guidelines,
clinical practice algorithms, and eventually in the
decision-making process of health insurances to re-
imburse PFR after LAR as standard care.
In case this study does not shows the hypothesized re-
sults, or in an insufficient amount, our considerations
are in line with the statements of Bols et al. [8] that the
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received physiotherapeutic interventions can still be of
value. The patients’ awareness and capability to coordi-
nate their pelvic floor system have increased, which are
positive and expected to be useful in the future for this
aging population.
Trial status
This is protocol version number 18 (approved 19 Septem-
ber 2019) of an ongoing trial. Recruitment started October
2017 and is expected to finish January 2020. Patient re-
cruitment has not been completed at the time of submis-
sion of this article.
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